Resources
In the News
Zeteo Biomedical Introduces ZEOx1 AquilaMD™ Ophthalmic Drug Delivery System
Zeteo’s patient-centric ophthalmic delivery systems are designed for precise, self-administration of preservative free drugs and biopharmaceuticals AUSTIN, TX – 01 June 2020 -- (PR.com) – Zeteo Biomedical LLC announced today the availability of the ZEOx1 AquilaMD™...
Zeteo Biomedical receives NIH Award to develop a universal nasal flu vaccine in collaboration with the Iowa State University Nanovaccine Institute
Vaccines that can be quickly manufactured, deployed and self-administered at global scale volumes is crucial to protect global populations against pandemic virus threats AUSTIN, TX – 20 May 2020 –(pr.com)-- Zeteo Biomedical LLC, Inc., a privately held, medical device...
Zeteo Biomedical Introduces ZEOx1 Orion™ Nasal Vaccine and Drug Delivery Systems
Zeteo’s patient-centric delivery systems are designed for quick manufacturing to facilitate rapid deployment of drugs and vaccines to global populations AUSTIN, TX – 14 May 2020 --(PR.com) – Zeteo Biomedical LLC announced today the availability of ZEOx1 Orion™ nasal...
Partners
The Nanovaccine Institute is a consortium of 70 researchers at 20 universities, research institutes, national laboratories, and companies, coordinated by Iowa State University. Our research is a transdisciplinary merger of expertise in immunology, nanotechnology, materials science, microbiology, neuroscience, cancer biology, gerontology, clinical science, and social science. We are developing nanovaccines and nanotherapeutics for respiratory infections, neural disorders, tropical diseases, cancer, aging, and veterinary diseases.